<DOC>
	<DOCNO>NCT00151957</DOCNO>
	<brief_summary>This study evaluate long-term safety MTS symptomatic treatment child age 6-12 diagnosed ADHD</brief_summary>
	<brief_title>Safety Tolerability SPD485 Children Aged 6-12 Diagnosed With ADHD Previously Participated MTS Trials</brief_title>
	<detailed_description>Attention-Deficit/Hyperactivity Disorder ( ADHD ) psychiatric disorder characterize 3 main symptom : inattention , hyperactivity impulsivity . This study evaluate long-term safety SPD485 symptomatic treatment child age 6-12 diagnosed ADHD</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Subject must participate complete SPD485201 participate complete minimum five seven week doubleblind treatment study SPD485302 . Subjects participate N17021 may enroll study follow completion End Study/Termination visit procedure . Females childbearing potential must negative urine pregnancy test Baseline must abstain sexual activity could result pregnancy , use acceptable contraceptive . Subject terminate SPD485102 , SPD495201 , SPD485302 OR N17021 noncompliance experience serious adverse event result termination antecedent protocol Female subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>